Rating scales for cognition in Huntington's disease: Critique and recommendations |
| |
| Authors: | Tiago A. Mestre MD MSc Anne‐Catherine Bachoud‐Lévi MD Johan Marinus PhD Julie C. Stout PhD Jane S. Paulsen PhD Kevin Duff PhD Cristina Sampaio MD PhD Christopher G. Goetz MD Esther Cubo MD Glenn T. Stebbins PhD Pablo Martinez‐Martin PhD the Members of the MDS Committee on Rating Scales Development |
| |
| Affiliation: | 1. Parkinson's Disease and Movement Disorders Center, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa Brain and Mind Institute, Ottawa, Ontario, Canada;2. Assistance Publique‐H?pitaux de Paris, National Centre of Reference for Huntington's Disease, Neurology Department;3. Université Paris Est, Créteil;4. INSERM U955 E01, Institut Mondor De Recherché Biomédicale, école Normale Supérieure, Créteil‐Paris, France;5. Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands;6. Institute of Cognitive and Clinical Neuroscience, School of Psychological Sciences, Monash University, Melbourne, Australia;7. Departments of Neurology, Psychiatry, Psychological and Brain Sciences, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA;8. Department of Neurology, Center for Alzheimer's Care, Imaging, and Research, University of Utah, Salt Lake City, Utah, USA;9. CHDI Foundation/CHDI Management, Princeton, NJ, USA;10. Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA;11. Department of Neurology, Hospital Universitário Hermanos Yagüe, Burgos, Spain;12. National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain |
| |
| Abstract: | Cognitive impairment is one of the main features of Huntington's disease and is present across the disease spectrum. As part of the International Parkinson's Disease and Movement Disorder Society‐sponsored project to review all clinical rating scales used in Huntington's disease, a systematic review of the literature was performed to identify cognitive scales used in Huntington's disease and make recommendations for their use. A total of 17 cognitive scales were identified and evaluated. None of the scales met criteria for a “recommended” status. For assessing severity of cognitive dysfunction, the Montreal Cognitive Assessment was “recommended with caveats.” The UHDRS Cognitive Assessment, the UHDRS‐For Advanced Patients cognitive section, the Alzheimer's Disease Assessment Scale‐Cognitive Subscale, the Frontal Assessment Battery, the Mattis Dementia Rating Scale, the Mini‐Mental State Examination, and the Repeatable Battery for the Assessment of Neuropsychological Status were “suggested” for evaluating severity of cognitive impairment. The MoCA was “suggested” as a screening tool for cognitive impairment. The major challenge in the assessment of cognition in Huntington's disease is the lack of a formal definition of dementia and/or mild cognitive impairment in this disease. The committee concluded that there is a need to further validate currently available cognitive scales in Huntington's disease, but that it is premature to recommend the development of new scales. Recently developed Huntington's disease‐specific scales, such as the Huntington's Disease‐Cognitive Assessment Battery, hold promise but require the completion of more comprehensive clinimetric development. © 2017 International Parkinson and Movement Disorder Society |
| |
| Keywords: | Huntington's disease cognition rating scales validation clinimetrics |
|
|
